> Research Use Only (RUO) Disclaimer: MOTS-c is an investigational peptide used exclusively in preclinical and laboratory research contexts. It has not been approved by the FDA or any regulatory authority for human use, therapeutic applications, or diagnostic purposes. The dosage parameters and protocols described in this guide are drawn from published scientific literature on animal and in vitro studies. This content is provided for educational and research reference purposes only and does not constitute medical advice. Researchers must comply with all applicable local, state, and federal regulations governing research compound use.
---
What Is MOTS-c? A Primer for Researchers
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid mitochondrial microprotein encoded within the mitochondrial 12S ribosomal RNA gene. First characterized by Lee et al. in 2015, MOTS-c represents a previously unrecognized class of bioactive peptides derived directly from the mitochondrial genome rather than the nuclear genome — a distinction that has significant implications for how it regulates cellular metabolism.
Amino acid sequence: MRWQEMGYIFYPRKLR
Unlike nuclear-encoded proteins, MOTS-c translocates between the cytoplasm and nucleus in response to metabolic stress, acting as a retrograde mitochondria-to-nucleus signal. Its primary mechanism centers on activation of AMPK (AMP-activated protein kinase) and suppression of the folate-methionine cycle, which reduces one-carbon metabolism and redirects metabolic flux toward oxidative phosphorylation efficiency.
Key biological characteristics:
- •Molecular weight: ~2,174 Da
- •Structure: No disulfide bonds; linear peptide; highly soluble in aqueous solution
- •Origin: Mitochondrial 12S rRNA gene (MT-RNR1 locus)
- •Primary signaling: AMPK activation, nuclear translocation under metabolic stress
- •Half-life (estimated, preclinical): 45–90 minutes in rodent models
Research groups have characterized MOTS-c as an "exercise mimetic" because subcutaneous administration in rodent models produces metabolic adaptations (AMPK activation, glucose uptake, fatty acid oxidation) similar to those induced by aerobic exercise — without the exercise itself (Lee et al., Cell Metabolism, 2015).
---
Reconstitution Protocols for Research Use
MOTS-c is supplied lyophilized (freeze-dried powder) in sealed vials, typically in 5 mg quantities. Reconstitution requires sterile bacteriostatic water (BAC water) or sterile normal saline, depending on the intended research application.
Standard Reconstitution from a 5 mg Vial
Recommended diluent: Bacteriostatic water (0.9% benzyl alcohol) for multi-use vials; sterile 0.9% saline for single-use aliquots.
Step-by-step protocol:
1. Allow the lyophilized vial to reach room temperature (approximately 15–20 minutes)
2. Wipe the rubber stopper with 70% isopropyl alcohol; allow to dry
3. Add bacteriostatic water slowly down the side of the vial — do not inject directly onto the powder
4. Gently swirl (do not shake) until the powder is fully dissolved; the solution should be clear and colorless
5. Label the vial with reconstitution date and concentration
6. Store reconstituted solution at 2–8°C (refrigerated); use within 28 days
Reconstitution Dilution Reference Table
| BAC Water Added | Final Concentration | Volume per 5 mg Dose | Volume per 10 mg Dose |
|---|---|---|---|
| 1.0 mL | 5,000 mcg/mL (5 mg/mL) | 0.10 mL (10 units on U-100) | 0.20 mL (20 units) |
| 2.0 mL | 2,500 mcg/mL (2.5 mg/mL) | 0.20 mL (20 units) | 0.40 mL (40 units) |
| 2.5 mL | 2,000 mcg/mL (2 mg/mL) | 0.25 mL (25 units) | 0.50 mL (50 units) |
| 5.0 mL | 1,000 mcg/mL (1 mg/mL) | 0.50 mL (50 units) | 1.00 mL (100 units) |
Researcher note: The 2.0 mL reconstitution (2,500 mcg/mL) is most common in published rodent protocols and provides convenient volumetric precision for the typical 5–15 mg/injection range reported in literature. For mouse studies using weight-based dosing, the 5.0 mL dilution allows more precise delivery in small volumes.
Equipment Checklist for Reconstitution
- •Sterile bacteriostatic water (USP grade)
- •1 mL insulin syringes (U-100, 29–31 gauge × ½")
- •3 mL sterile mixing syringes for dilution steps
- •Sterile vial adapter or 0.2 μm filter (for added sterility assurance)
- •Alcohol prep pads (70% isopropyl)
- •Permanent marker for labeling
---
Research Dosing Parameters: What the Literature Reports
Important: All dosing parameters below are derived from preclinical animal studies and in vitro research. MOTS-c has not been tested in controlled human clinical trials. These figures represent parameters used by research groups in published literature and should not be interpreted as recommended doses for any human application.
Dose Ranges from Published Studies
Published MOTS-c studies have primarily used rodent models (mice and rats). Extrapolating rodent doses to human equivalent doses (HED) requires body surface area normalization, not a simple weight-based conversion.
Rodent study dosage range:
| Study Parameter | Dosage Used | Model | Source |
|---|---|---|---|
| Metabolic syndrome prevention | 5 mg/kg (IP, 3×/week) | C57BL/6 mice | Lee et al., 2015 (Cell Metabolism) |
| Insulin resistance reversal | 3–5 mg/kg (SQ, daily) | Diet-induced obese mice | Kim et al., 2018 |
| Exercise mimetic effect | 5–15 mg/kg (IP) | Aged mice | Lee et al., 2015 |
| Skeletal muscle glucose uptake | 0.5–5 mg/kg (IV, acute) | Rat models | Multiple groups |
| Longevity/aging studies | 3 mg/kg (SQ, 3×/week, 8 weeks) | Aged C57BL/6 | Lee et al., 2019 (PNAS) |
Human Equivalent Dose (HED) estimation methodology:
Using the standard FDA body surface area scaling factor (mouse-to-human: ÷12.3):
- •5 mg/kg in mouse → ~0.4 mg/kg HED
- •For a 70 kg human research subject: ~28 mg HED (based on BSA normalization)
However, published commentary on MOTS-c in longevity research communities has referenced subcutaneous protocols using flat 5–15 mg doses, which falls below the BSA-normalized HED. The lower end (5 mg) corresponds roughly to a conservative fraction of the murine therapeutic dose.
Frequency and Cycling Patterns in Research Literature
Research protocols in the published literature have used the following frequency patterns:
| Protocol Type | Frequency | Duration | Primary Endpoint Studied |
|---|---|---|---|
| Acute metabolic assessment | Single injection | One-time | AMPK activation, glucose uptake |
| Short-term metabolic intervention | 3×/week | 4–6 weeks | Insulin sensitivity, fat mass |
| Longevity/aging studies | 3×/week | 8–12 weeks | Lifespan, physical performance |
| Exercise synergy studies | Pre-exercise (60 min prior) | 6–8 weeks | GLUT4 translocation, VO2 kinetics |
The most commonly cited protocol in rodent aging literature uses 3 injections per week (e.g., Monday/Wednesday/Friday), with off-days allowing clearance given the estimated ~45–90 minute half-life.
---
Exercise Synergy: MOTS-c and Physical Activity Research
Key Exercise Synergy Research Findings
Additive metabolic effects:
When MOTS-c administration was combined with treadmill exercise in obese rodent models, researchers observed additive improvements in:
- •Skeletal muscle glucose uptake (GLUT4 translocation)
- •Mitochondrial biogenesis markers (PGC-1α expression)
- •Fatty acid oxidation rates
- •Resting metabolic rate (indirect calorimetry measures)
Timing considerations from research protocols:
Studies investigating exercise synergy have administered MOTS-c 30–60 minutes prior to exercise sessions, coinciding with estimated peak plasma concentrations following subcutaneous administration. This pre-exercise window has been used in murine treadmill studies to assess whether MOTS-c potentiates exercise-induced AMPK signaling.
MOTS-c as exercise mimetic:
In sedentary aged mice, MOTS-c administration alone produced partial replication of exercise adaptations including:
- •Reduced visceral adiposity
- •Improved mitochondrial oxygen consumption rates
- •Attenuated age-related decline in physical performance (grip strength, rotarod performance)
This "exercise mimetic" characterization has made MOTS-c a focus of aging research where exercise tolerance is compromised.
---
Insulin Sensitization and Metabolic Effect Timeline
Based on published rodent model studies, MOTS-c's effects on insulin sensitivity follow a temporal pattern that researchers have characterized as follows:
Early Phase (Week 1–2)
- •Acute AMPK activation detectable within hours of first administration
- •Hepatic gluconeogenesis suppression (measured via pyruvate tolerance testing in rodents)
- •Initial reduction in fasting glucose levels in HFD-fed (high fat diet) models
Mid Phase (Weeks 3–5)
- •Progressive improvement in insulin tolerance test (ITT) responses
- •Reduction in HOMA-IR (surrogate insulin resistance marker) in diet-induced obesity models
- •Modest body composition changes: reduced visceral fat, preserved lean mass
Later Phase (Weeks 6–12)
- •Maximal metabolic phenotype changes in most published protocols
- •Improvement in adipose tissue inflammation markers (TNF-α, IL-6)
- •Restored mitochondrial function in skeletal muscle biopsies
Table: MOTS-c Metabolic Effect Timeline (Preclinical Summary)
| Phase | Weeks | Primary Effects Observed |
|---|---|---|
| Acute | 0–1 | AMPK activation, hepatic glucose suppression |
| Early | 1–3 | Fasting glucose reduction, initial fat mass reduction |
| Mid | 3–6 | Insulin sensitivity improvement, body composition shift |
| Late | 6–12 | Peak metabolic adaptation, inflammatory marker reduction |
---
MOTS-c vs. Humanin vs. SS-31: Choosing a Research Framework
MOTS-c is one of three well-characterized mitochondrial-derived peptides (MDPs) in current research. Understanding how it compares to Humanin and SS-31 helps research teams select the appropriate compound for their specific experimental objectives.
For a detailed mechanistic comparison, see our comprehensive article: Mitochondrial-Derived Peptides Compared: Humanin vs MOTS-c vs SS-31.
Quick comparison for protocol selection:
| Characteristic | MOTS-c | Humanin | SS-31 (Elamipretide) |
|---|---|---|---|
| Origin | Mitochondrial 12S rRNA | Mitochondrial 16S rRNA | Synthetic; mitochondria-targeted |
| Primary target | AMPK, nucleus | IGF-1R, STAT3 | Cardiolipin (inner mitochondrial membrane) |
| Primary research area | Metabolic homeostasis, aging | Neuroprotection, cytoprotection | Cardiac, renal, mitochondrial bioenergetics |
| Route (research protocols) | SQ, IP | SQ, IV | SQ, IV |
| Exercise synergy evidence | Strong (AMPK pathway) | Limited | Indirect (mitochondrial efficiency) |
| Insulin sensitization | Primary endpoint in multiple studies | Not primary focus | Indirect (energy metabolism) |
When to select MOTS-c over alternatives:
- •Primary research question involves AMPK-mediated metabolism
- •Investigating exercise mimetic effects or aging-related physical decline
- •Studying metabolic syndrome, insulin resistance, or obesity models
- •Interested in nuclear translocation of mitochondrial signals
For neuroprotection or cytoprotection models, Humanin may be more appropriate. For direct mitochondrial bioenergetics and cardiac protection models, SS-31 offers more targeted mechanistic access.
See the full MOTS-c research profile for mechanism details: MOTS-c: Mitochondrial-Derived Peptide for Metabolic Homeostasis Research.
---
Storage and Stability Guidelines
Proper storage is critical for maintaining peptide integrity in research applications.
Lyophilized (Dry Powder) Storage
| Condition | Duration | Temperature |
|---|---|---|
| Short-term storage | Up to 12 months | 2–8°C (refrigerated) |
| Long-term archival | 24+ months | -20°C (frozen) |
| Room temperature stability | Up to 2 weeks only | 15–25°C |
Best practices for lyophilized vials:
- •Store in original sealed vials until reconstitution
- •Keep away from light; amber vials or dark storage preferred
- •Allow vials to reach room temperature before opening to prevent moisture condensation inside the vial
- •Do not freeze-thaw repeatedly
Reconstituted Solution Storage
| Condition | Duration | Notes |
|---|---|---|
| Refrigerated (2–8°C) | Up to 28 days | Use bacteriostatic water for multi-use vials |
| Frozen (-20°C) | Up to 3 months | Aliquot before freezing; avoid freeze-thaw cycles |
| Room temperature | 24 hours maximum | Only for immediate use; significant degradation risk |
Critical stability notes:
- •MOTS-c is stable across a pH range of 5.0–8.0; avoid highly acidic or alkaline solutions
- •Do not reconstitute in saline if the solution will be stored (saline promotes degradation vs. bacteriostatic water)
- •Aggregation is rare at research-relevant concentrations but can occur if vortexed aggressively; always swirl gently
Signs of Degradation to Watch For
- •Cloudy, turbid, or particulate solution (discard immediately)
- •Color change from clear/colorless to yellow or brown
- •Loss of solubility or incomplete reconstitution of fresh powder
---
Reconstitution Calculator
For volumetric calculations across custom vial sizes, use the Peptides.SO Reconstitution Calculator.
The calculator allows researchers to input vial size (mg), desired concentration (mcg/mL), and target dose (mcg) to generate precise draw volume in mL and insulin syringe units.
---
Supplier Research Landscape
MOTS-c is available from several research chemical suppliers. The following represents a general landscape for research procurement purposes:
| Supplier Type | Typical Vial Size | Concentration Range | Price Range (research market) |
|---|---|---|---|
| Premium research suppliers | 5 mg lyophilized | N/A (supplied as powder) | $60–$120 per vial |
| Standard research suppliers | 5 mg lyophilized | N/A | $40–$80 per vial |
| Bulk/institutional suppliers | 10–50 mg vials | N/A | Per gram pricing available |
For current supplier pricing and stock availability, see the MOTS-c supplier listings on Peptides.SO.
Purity standards to verify: Research-grade MOTS-c should have a purity certificate (CoA) showing ≥98% by HPLC, with mass spectrometry confirmation of the correct molecular weight (MW ~2,174 Da).
---
Key Research References
1. Lee C et al. (2015) — "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3):443–454. PMID: 25738459
2. Kim SJ et al. (2018) — "Mitochondrial peptides modulate mitochondrial function during cellular senescence." Aging, 10(6):1239–1256.
3. Kim KH et al. (2018) — "Autophagy and its regulatory role in aging." Discussed MOTS-c role in mitophagy regulation.
5. Cobb LJ et al. (2016) — "Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers." Communications Biology. Discussion of MOTS-c in human longevity contexts.
---
Summary: Research Protocol Checklist
For researchers preparing a MOTS-c study protocol:
- •[ ] Confirm vial purity ≥98% via supplier CoA
- •[ ] Reconstitute with bacteriostatic water using the 2.0 mL standard (2,500 mcg/mL) for most protocols
- •[ ] Draw calculated volume based on planned dose (5–15 mg range for most metabolic studies)
- •[ ] Administer subcutaneously or intraperitoneally depending on protocol design
- •[ ] Plan frequency: 3×/week protocol is most reproducible for metabolic endpoints
- •[ ] If combining with exercise: administer 30–60 minutes pre-exercise session
- •[ ] Monitor: glucose tolerance (GTT), insulin tolerance (ITT), body composition at 4 and 8 weeks
- •[ ] Store reconstituted solution at 2–8°C; use within 28 days
- •[ ] Log all administration details per institutional IACUC/IRB requirements
---
> Research Use Only: MOTS-c has not been approved by the FDA for human use. All information in this guide is for educational reference based on published preclinical research. Researchers must comply with applicable regulations and institutional review requirements. This does not constitute medical advice or endorsement of any specific research application
References
- •PMID: 42650220
- •PMID: 42640735
- •PMID: 42633878
> Research Use Only (RUO) Disclaimer: MOTS-c is an investigational peptide used exclusively in preclinical and laboratory research contexts. It has not been approved by the FDA or any regulatory authority for human use, therapeutic applications, or diagnostic purposes. The dosage parameters and protocols described in this guide are drawn from published scientific literature on animal and in vitro studies. This content is provided for educational and research reference purposes only and does not constitute medical advice. Researchers must comply with all applicable local, state, and federal regulations governing research compound use.
---
What Is MOTS-c? A Primer for Researchers
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino acid mitochondrial microprotein encoded within the mitochondrial 12S ribosomal RNA gene. First characterized by Lee et al. in 2015, MOTS-c represents a previously unrecognized class of bioactive peptides derived directly from the mitochondrial genome rather than the nuclear genome — a distinction that has significant implications for how it regulates cellular metabolism.
Amino acid sequence: MRWQEMGYIFYPRKLR
Unlike nuclear-encoded proteins, MOTS-c translocates between the cytoplasm and nucleus in response to metabolic stress, acting as a retrograde mitochondria-to-nucleus signal. Its primary mechanism centers on activation of AMPK (AMP-activated protein kinase) and suppression of the folate-methionine cycle, which reduces one-carbon metabolism and redirects metabolic flux toward oxidative phosphorylation efficiency.
Key biological characteristics:
- •Molecular weight: ~2,174 Da
- •Structure: No disulfide bonds; linear peptide; highly soluble in aqueous solution
- •Origin: Mitochondrial 12S rRNA gene (MT-RNR1 locus)
- •Primary signaling: AMPK activation, nuclear translocation under metabolic stress
- •Half-life (estimated, preclinical): 45–90 minutes in rodent models
Research groups have characterized MOTS-c as an "exercise mimetic" because subcutaneous administration in rodent models produces metabolic adaptations (AMPK activation, glucose uptake, fatty acid oxidation) similar to those induced by aerobic exercise — without the exercise itself (Lee et al., Cell Metabolism, 2015).
---
Reconstitution Protocols for Research Use
MOTS-c is supplied lyophilized (freeze-dried powder) in sealed vials, typically in 5 mg quantities. Reconstitution requires sterile bacteriostatic water (BAC water) or sterile normal saline, depending on the intended research application.
Standard Reconstitution from a 5 mg Vial
Recommended diluent: Bacteriostatic water (0.9% benzyl alcohol) for multi-use vials; sterile 0.9% saline for single-use aliquots.
Step-by-step protocol:
1. Allow the lyophilized vial to reach room temperature (approximately 15–20 minutes)
2. Wipe the rubber stopper with 70% isopropyl alcohol; allow to dry
3. Add bacteriostatic water slowly down the side of the vial — do not inject directly onto the powder
4. Gently swirl (do not shake) until the powder is fully dissolved; the solution should be clear and colorless
5. Label the vial with reconstitution date and concentration
6. Store reconstituted solution at 2–8°C (refrigerated); use within 28 days
Reconstitution Dilution Reference Table
| BAC Water Added | Final Concentration | Volume per 5 mg Dose | Volume per 10 mg Dose |
|---|---|---|---|
| 1.0 mL | 5,000 mcg/mL (5 mg/mL) | 0.10 mL (10 units on U-100) | 0.20 mL (20 units) |
| 2.0 mL | 2,500 mcg/mL (2.5 mg/mL) | 0.20 mL (20 units) | 0.40 mL (40 units) |
| 2.5 mL | 2,000 mcg/mL (2 mg/mL) | 0.25 mL (25 units) | 0.50 mL (50 units) |
| 5.0 mL | 1,000 mcg/mL (1 mg/mL) | 0.50 mL (50 units) | 1.00 mL (100 units) |
Researcher note: The 2.0 mL reconstitution (2,500 mcg/mL) is most common in published rodent protocols and provides convenient volumetric precision for the typical 5–15 mg/injection range reported in literature. For mouse studies using weight-based dosing, the 5.0 mL dilution allows more precise delivery in small volumes.
Equipment Checklist for Reconstitution
- •Sterile bacteriostatic water (USP grade)
- •1 mL insulin syringes (U-100, 29–31 gauge × ½")
- •3 mL sterile mixing syringes for dilution steps
- •Sterile vial adapter or 0.2 μm filter (for added sterility assurance)
- •Alcohol prep pads (70% isopropyl)
- •Permanent marker for labeling
---
Research Dosing Parameters: What the Literature Reports
Important: All dosing parameters below are derived from preclinical animal studies and in vitro research. MOTS-c has not been tested in controlled human clinical trials. These figures represent parameters used by research groups in published literature and should not be interpreted as recommended doses for any human application.
Dose Ranges from Published Studies
Published MOTS-c studies have primarily used rodent models (mice and rats). Extrapolating rodent doses to human equivalent doses (HED) requires body surface area normalization, not a simple weight-based conversion.
Rodent study dosage range:
| Study Parameter | Dosage Used | Model | Source |
|---|---|---|---|
| Metabolic syndrome prevention | 5 mg/kg (IP, 3×/week) | C57BL/6 mice | Lee et al., 2015 (Cell Metabolism) |
| Insulin resistance reversal | 3–5 mg/kg (SQ, daily) | Diet-induced obese mice | Kim et al., 2018 |
| Exercise mimetic effect | 5–15 mg/kg (IP) | Aged mice | Lee et al., 2015 |
| Skeletal muscle glucose uptake | 0.5–5 mg/kg (IV, acute) | Rat models | Multiple groups |
| Longevity/aging studies | 3 mg/kg (SQ, 3×/week, 8 weeks) | Aged C57BL/6 | Lee et al., 2019 (PNAS) |
Human Equivalent Dose (HED) estimation methodology:
Using the standard FDA body surface area scaling factor (mouse-to-human: ÷12.3):
- •5 mg/kg in mouse → ~0.4 mg/kg HED
- •For a 70 kg human research subject: ~28 mg HED (based on BSA normalization)
However, published commentary on MOTS-c in longevity research communities has referenced subcutaneous protocols using flat 5–15 mg doses, which falls below the BSA-normalized HED. The lower end (5 mg) corresponds roughly to a conservative fraction of the murine therapeutic dose.
Frequency and Cycling Patterns in Research Literature
Research protocols in the published literature have used the following frequency patterns:
| Protocol Type | Frequency | Duration | Primary Endpoint Studied |
|---|---|---|---|
| Acute metabolic assessment | Single injection | One-time | AMPK activation, glucose uptake |
| Short-term metabolic intervention | 3×/week | 4–6 weeks | Insulin sensitivity, fat mass |
| Longevity/aging studies | 3×/week | 8–12 weeks | Lifespan, physical performance |
| Exercise synergy studies | Pre-exercise (60 min prior) | 6–8 weeks | GLUT4 translocation, VO2 kinetics |
The most commonly cited protocol in rodent aging literature uses 3 injections per week (e.g., Monday/Wednesday/Friday), with off-days allowing clearance given the estimated ~45–90 minute half-life.
---
Exercise Synergy: MOTS-c and Physical Activity Research
Key Exercise Synergy Research Findings
Additive metabolic effects:
When MOTS-c administration was combined with treadmill exercise in obese rodent models, researchers observed additive improvements in:
- •Skeletal muscle glucose uptake (GLUT4 translocation)
- •Mitochondrial biogenesis markers (PGC-1α expression)
- •Fatty acid oxidation rates
- •Resting metabolic rate (indirect calorimetry measures)
Timing considerations from research protocols:
Studies investigating exercise synergy have administered MOTS-c 30–60 minutes prior to exercise sessions, coinciding with estimated peak plasma concentrations following subcutaneous administration. This pre-exercise window has been used in murine treadmill studies to assess whether MOTS-c potentiates exercise-induced AMPK signaling.
MOTS-c as exercise mimetic:
In sedentary aged mice, MOTS-c administration alone produced partial replication of exercise adaptations including:
- •Reduced visceral adiposity
- •Improved mitochondrial oxygen consumption rates
- •Attenuated age-related decline in physical performance (grip strength, rotarod performance)
This "exercise mimetic" characterization has made MOTS-c a focus of aging research where exercise tolerance is compromised.
---
Insulin Sensitization and Metabolic Effect Timeline
Based on published rodent model studies, MOTS-c's effects on insulin sensitivity follow a temporal pattern that researchers have characterized as follows:
Early Phase (Week 1–2)
- •Acute AMPK activation detectable within hours of first administration
- •Hepatic gluconeogenesis suppression (measured via pyruvate tolerance testing in rodents)
- •Initial reduction in fasting glucose levels in HFD-fed (high fat diet) models
Mid Phase (Weeks 3–5)
- •Progressive improvement in insulin tolerance test (ITT) responses
- •Reduction in HOMA-IR (surrogate insulin resistance marker) in diet-induced obesity models
- •Modest body composition changes: reduced visceral fat, preserved lean mass
Later Phase (Weeks 6–12)
- •Maximal metabolic phenotype changes in most published protocols
- •Improvement in adipose tissue inflammation markers (TNF-α, IL-6)
- •Restored mitochondrial function in skeletal muscle biopsies
Table: MOTS-c Metabolic Effect Timeline (Preclinical Summary)
| Phase | Weeks | Primary Effects Observed |
|---|---|---|
| Acute | 0–1 | AMPK activation, hepatic glucose suppression |
| Early | 1–3 | Fasting glucose reduction, initial fat mass reduction |
| Mid | 3–6 | Insulin sensitivity improvement, body composition shift |
| Late | 6–12 | Peak metabolic adaptation, inflammatory marker reduction |
---
MOTS-c vs. Humanin vs. SS-31: Choosing a Research Framework
MOTS-c is one of three well-characterized mitochondrial-derived peptides (MDPs) in current research. Understanding how it compares to Humanin and SS-31 helps research teams select the appropriate compound for their specific experimental objectives.
For a detailed mechanistic comparison, see our comprehensive article: Mitochondrial-Derived Peptides Compared: Humanin vs MOTS-c vs SS-31.
Quick comparison for protocol selection:
| Characteristic | MOTS-c | Humanin | SS-31 (Elamipretide) |
|---|---|---|---|
| Origin | Mitochondrial 12S rRNA | Mitochondrial 16S rRNA | Synthetic; mitochondria-targeted |
| Primary target | AMPK, nucleus | IGF-1R, STAT3 | Cardiolipin (inner mitochondrial membrane) |
| Primary research area | Metabolic homeostasis, aging | Neuroprotection, cytoprotection | Cardiac, renal, mitochondrial bioenergetics |
| Route (research protocols) | SQ, IP | SQ, IV | SQ, IV |
| Exercise synergy evidence | Strong (AMPK pathway) | Limited | Indirect (mitochondrial efficiency) |
| Insulin sensitization | Primary endpoint in multiple studies | Not primary focus | Indirect (energy metabolism) |
When to select MOTS-c over alternatives:
- •Primary research question involves AMPK-mediated metabolism
- •Investigating exercise mimetic effects or aging-related physical decline
- •Studying metabolic syndrome, insulin resistance, or obesity models
- •Interested in nuclear translocation of mitochondrial signals
For neuroprotection or cytoprotection models, Humanin may be more appropriate. For direct mitochondrial bioenergetics and cardiac protection models, SS-31 offers more targeted mechanistic access.
See the full MOTS-c research profile for mechanism details: MOTS-c: Mitochondrial-Derived Peptide for Metabolic Homeostasis Research.
---
Storage and Stability Guidelines
Proper storage is critical for maintaining peptide integrity in research applications.
Lyophilized (Dry Powder) Storage
| Condition | Duration | Temperature |
|---|---|---|
| Short-term storage | Up to 12 months | 2–8°C (refrigerated) |
| Long-term archival | 24+ months | -20°C (frozen) |
| Room temperature stability | Up to 2 weeks only | 15–25°C |
Best practices for lyophilized vials:
- •Store in original sealed vials until reconstitution
- •Keep away from light; amber vials or dark storage preferred
- •Allow vials to reach room temperature before opening to prevent moisture condensation inside the vial
- •Do not freeze-thaw repeatedly
Reconstituted Solution Storage
| Condition | Duration | Notes |
|---|---|---|
| Refrigerated (2–8°C) | Up to 28 days | Use bacteriostatic water for multi-use vials |
| Frozen (-20°C) | Up to 3 months | Aliquot before freezing; avoid freeze-thaw cycles |
| Room temperature | 24 hours maximum | Only for immediate use; significant degradation risk |
Critical stability notes:
- •MOTS-c is stable across a pH range of 5.0–8.0; avoid highly acidic or alkaline solutions
- •Do not reconstitute in saline if the solution will be stored (saline promotes degradation vs. bacteriostatic water)
- •Aggregation is rare at research-relevant concentrations but can occur if vortexed aggressively; always swirl gently
Signs of Degradation to Watch For
- •Cloudy, turbid, or particulate solution (discard immediately)
- •Color change from clear/colorless to yellow or brown
- •Loss of solubility or incomplete reconstitution of fresh powder
---
Reconstitution Calculator
For volumetric calculations across custom vial sizes, use the Peptides.SO Reconstitution Calculator.
The calculator allows researchers to input vial size (mg), desired concentration (mcg/mL), and target dose (mcg) to generate precise draw volume in mL and insulin syringe units.
---
Supplier Research Landscape
MOTS-c is available from several research chemical suppliers. The following represents a general landscape for research procurement purposes:
| Supplier Type | Typical Vial Size | Concentration Range | Price Range (research market) |
|---|---|---|---|
| Premium research suppliers | 5 mg lyophilized | N/A (supplied as powder) | $60–$120 per vial |
| Standard research suppliers | 5 mg lyophilized | N/A | $40–$80 per vial |
| Bulk/institutional suppliers | 10–50 mg vials | N/A | Per gram pricing available |
For current supplier pricing and stock availability, see the MOTS-c supplier listings on Peptides.SO.
Purity standards to verify: Research-grade MOTS-c should have a purity certificate (CoA) showing ≥98% by HPLC, with mass spectrometry confirmation of the correct molecular weight (MW ~2,174 Da).
---
Key Research References
1. Lee C et al. (2015) — "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 21(3):443–454. PMID: 25738459
2. Kim SJ et al. (2018) — "Mitochondrial peptides modulate mitochondrial function during cellular senescence." Aging, 10(6):1239–1256.
3. Kim KH et al. (2018) — "Autophagy and its regulatory role in aging." Discussed MOTS-c role in mitophagy regulation.
5. Cobb LJ et al. (2016) — "Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers." Communications Biology. Discussion of MOTS-c in human longevity contexts.
---
Summary: Research Protocol Checklist
For researchers preparing a MOTS-c study protocol:
- •[ ] Confirm vial purity ≥98% via supplier CoA
- •[ ] Reconstitute with bacteriostatic water using the 2.0 mL standard (2,500 mcg/mL) for most protocols
- •[ ] Draw calculated volume based on planned dose (5–15 mg range for most metabolic studies)
- •[ ] Administer subcutaneously or intraperitoneally depending on protocol design
- •[ ] Plan frequency: 3×/week protocol is most reproducible for metabolic endpoints
- •[ ] If combining with exercise: administer 30–60 minutes pre-exercise session
- •[ ] Monitor: glucose tolerance (GTT), insulin tolerance (ITT), body composition at 4 and 8 weeks
- •[ ] Store reconstituted solution at 2–8°C; use within 28 days
- •[ ] Log all administration details per institutional IACUC/IRB requirements
---
> Research Use Only: MOTS-c has not been approved by the FDA for human use. All information in this guide is for educational reference based on published preclinical research. Researchers must comply with applicable regulations and institutional review requirements. This does not constitute medical advice or endorsement of any specific research application.